These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
359 related articles for article (PubMed ID: 32166597)
1. Delgocitinib: First Approval. Dhillon S Drugs; 2020 Apr; 80(6):609-615. PubMed ID: 32166597 [TBL] [Abstract][Full Text] [Related]
2. Discovery of a Janus Kinase Inhibitor Bearing a Highly Three-Dimensional Spiro Scaffold: JTE-052 (Delgocitinib) as a New Dermatological Agent to Treat Inflammatory Skin Disorders. Noji S; Hara Y; Miura T; Yamanaka H; Maeda K; Hori A; Yamamoto H; Obika S; Inoue M; Hase Y; Orita T; Doi S; Adachi T; Tanimoto A; Oki C; Kimoto Y; Ogawa Y; Negoro T; Hashimoto H; Shiozaki M J Med Chem; 2020 Jul; 63(13):7163-7185. PubMed ID: 32511913 [TBL] [Abstract][Full Text] [Related]
3. Long-term safety and efficacy of delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with atopic dermatitis. Nakagawa H; Nemoto O; Igarashi A; Saeki H; Murata R; Kaino H; Nagata T J Dermatol; 2020 Feb; 47(2):114-120. PubMed ID: 31820485 [TBL] [Abstract][Full Text] [Related]
4. Role of janus kinase inhibitors in the treatment of alopecia areata. Triyangkulsri K; Suchonwanit P Drug Des Devel Ther; 2018; 12():2323-2335. PubMed ID: 30100707 [TBL] [Abstract][Full Text] [Related]
5. Abrocitinib: First Globally Approved Selective Janus Kinase-1 Inhibitor for the Treatment of Atopic Dermatitis. De SK Curr Med Chem; 2023; 30(38):4278-4282. PubMed ID: 36797599 [TBL] [Abstract][Full Text] [Related]
6. Delgocitinib in atopic dermatitis. Ho J; Molin S Drugs Today (Barc); 2021 Dec; 57(12):719-731. PubMed ID: 34909801 [TBL] [Abstract][Full Text] [Related]
7. Delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with moderate to severe atopic dermatitis: A phase 3, randomized, double-blind, vehicle-controlled study and an open-label, long-term extension study. Nakagawa H; Nemoto O; Igarashi A; Saeki H; Kaino H; Nagata T J Am Acad Dermatol; 2020 Apr; 82(4):823-831. PubMed ID: 32029304 [TBL] [Abstract][Full Text] [Related]
9. Innovation in the treatment of atopic dermatitis: Emerging topical and oral Janus kinase inhibitors. Nakashima C; Yanagihara S; Otsuka A Allergol Int; 2022 Jan; 71(1):40-46. PubMed ID: 34815171 [TBL] [Abstract][Full Text] [Related]
10. Targeting the Janus Kinase Family in Autoimmune Skin Diseases. Howell MD; Kuo FI; Smith PA Front Immunol; 2019; 10():2342. PubMed ID: 31649667 [TBL] [Abstract][Full Text] [Related]
11. The pan-JAK inhibitor delgocitinib in a cream formulation demonstrates dose response in chronic hand eczema in a 16-week randomized phase IIb trial. Worm M; Thyssen JP; Schliemann S; Bauer A; Shi VY; Ehst B; Tillmann S; Korn S; Resen K; Agner T Br J Dermatol; 2022 Jul; 187(1):42-51. PubMed ID: 35084738 [TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of topical delgocitinib in patients with chronic hand eczema: data from a randomized, double-blind, vehicle-controlled phase IIa study. Worm M; Bauer A; Elsner P; Mahler V; Molin S; Nielsen TSS Br J Dermatol; 2020 May; 182(5):1103-1110. PubMed ID: 31466119 [TBL] [Abstract][Full Text] [Related]
13. Janus kinase inhibitor delgocitinib suppresses pruritus and nerve elongation in an atopic dermatitis murine model. Yamamoto Y; Otsuka A; Nakashima C; Ishida Y; Honda T; Egawa G; Amano W; Usui K; Hamada Y; Wada M; Tanimoto A; Konishi N; Hayashi M; Matsushita M; Kabashima K J Dermatol Sci; 2020 Feb; 97(2):161-164. PubMed ID: 31924380 [No Abstract] [Full Text] [Related]
14. English version of Japanese guidance for the use of oral Janus kinase (JAK) inhibitors in the treatments of atopic dermatitis. Saeki H; Akiyama M; Abe M; Igarashi A; Imafuku S; Ohya Y; Katoh N; Kameda H; Kabashima K; Tsunemi Y; Hide M; Ohtsuki M; J Dermatol; 2023 Jan; 50(1):e1-e19. PubMed ID: 36412059 [TBL] [Abstract][Full Text] [Related]
15. Delgocitinib ointment in pediatric patients with atopic dermatitis: A phase 3, randomized, double-blind, vehicle-controlled study and a subsequent open-label, long-term study. Nakagawa H; Nemoto O; Igarashi A; Saeki H; Kabashima K; Oda M; Nagata T J Am Acad Dermatol; 2021 Oct; 85(4):854-862. PubMed ID: 34118298 [TBL] [Abstract][Full Text] [Related]
16. Janus kinase inhibitors for the therapy of atopic dermatitis. Traidl S; Freimooser S; Werfel T Allergol Select; 2021; 5():293-304. PubMed ID: 34532638 [TBL] [Abstract][Full Text] [Related]
17. Discovery and Characterization of the Topical Soft JAK Inhibitor CEE321 for Atopic Dermatitis. Thoma G; Duthaler RO; Waelchli R; Hauchard A; Bruno S; Strittmatter-Keller U; Orjuela Leon A; Viebrock S; Aichholz R; Beltz K; Grove K; Hoque S; Rudewicz PJ; Zerwes HG J Med Chem; 2023 Feb; 66(3):2161-2168. PubMed ID: 36657024 [TBL] [Abstract][Full Text] [Related]
18. A phase 2a randomized vehicle-controlled multi-center study of the safety and efficacy of delgocitinib in subjects with moderate-to-severe alopecia areata. Mikhaylov D; Glickman JW; Del Duca E; Nia J; Hashim P; Singer GK; Posligua AL; Florek AG; Ibler E; Hagstrom EL; Estrada Y; Rangel SM; Colavincenzo M; Paller AS; Guttman-Yassky E Arch Dermatol Res; 2023 Mar; 315(2):181-189. PubMed ID: 35230488 [TBL] [Abstract][Full Text] [Related]
19. Application of Sequential Palladium Catalysis for the Discovery of Janus Kinase Inhibitors in the Benzo[ c]pyrrolo[2,3- h][1,6]naphthyridin-5-one (BPN) Series. Elsayed MSA; Nielsen JJ; Park S; Park J; Liu Q; Kim CH; Pommier Y; Agama K; Low PS; Cushman M J Med Chem; 2018 Dec; 61(23):10440-10462. PubMed ID: 30460842 [TBL] [Abstract][Full Text] [Related]
20. JAK inhibitor: Introduction. Raychaudhuri SP; Raychaudhuri SK Indian J Dermatol Venereol Leprol; 2023; 89(5):688-690. PubMed ID: 37609754 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]